Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-04-2009 | Original Paper

Association of leptin −2548G/A and leptin receptor Q223R polymorphisms with increased risk for oral cancer

Authors: Christos Yapijakis, Michael Kechagiadakis, Emeka Nkenke, Zoe Serefoglou, Dimitrios Avgoustidis, Antonis Vylliotis, Despina Perrea, Friedrich W. Neukam, Efstratios Patsouris, Eleftherios Vairaktaris

Published in: Journal of Cancer Research and Clinical Oncology | Issue 4/2009

Abstract

Purpose

We investigated the possible association of DNA polymorphisms −2548G/A and Q223R in the leptin (LEP) and leptin receptor (LEPR) genes, respectively, which both affect the amount of circulating cytokine-type hormone leptin, with risk for development of oral cancer.

Methods

Polymerase chain reaction-based restriction analysis was performed in DNA samples of 150 patients with oral squamous cell carcinoma (OSCC) and 152 healthy control subjects of equivalent gender, age, and ethnicity (Greeks and Germans).

Results

Compared to controls, the homozygous high gene expression genotype A/A of the LEP −2548G/A polymorphism was significantly increased in the subgroups of patients with advanced cancer stages (P = 0.0001; OR 9.0, 95% CI 2.62–30.89), with a positive family history of cancer (P = 0.0346; OR 3.55, 95% CI 1.15–11.01), without tobacco abuse (P = 0.0051; OR 9.69, 95% CI 1.03–91.24), and without alcohol abuse (P = 0.0472; OR 2.16, 95% CI 0.87–5.37). The homozygous low-leptin-binding genotype G/G of the LEPR Q223R polymorphism was strongly associated with an increased risk for OSCC for all patients (P = 0.0028; OR 4.11, 95% CI 1.30–12.97) as well for most of the patient subgroups.

Conclusions

The above findings are consistent with the growth-promoting role of leptin in cancer and its induction effect on angiogenesis and metastasis. This is the first study indicating the association of these LEP and LEPR gene polymorphisms with increased risk for OSCC.

Attoub S, Noe V, Pirola L, Bruyneel E, Chastre E, Mareel M, Wymann MP, Gespach C (2000) Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho and rac-dependent signalling pathways. FASEB J 14:2329–2338. doi:10.1096/fj.00-0162 PubMedCrossRef

Bodary PF, Westrick RJ, Wickenheiser KJ, Shen Y, Eitzman DT (2002) Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA 287:1706–1709. doi:10.1001/jama.287.13.1706 PubMedCrossRef

Bouloumie A, Drexler HC, Lafontan M, Busse R (1998) Leptin the product of Ob gene, promotes angiogenesis. Circ Res 269:546–549

De Matteis R, Puxeddu R, Riva A, Cinti S (2002) Intraobular ducts of human major salivary glands contain leptin an dits receptor. J Anat 201:363–370. doi:10.1046/j.0021-8782.2002.00106.x PubMedCrossRef

Dieudonne M-N, Machinal-quelin F, Serazin-Leroy V, Leneveu M-C, Pecquery R, Giudicelli Y (2002) Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun 293:622–628. doi:10.1016/S0006-291X(02)00205-X PubMedCrossRef

Endo K, Yanagi H, Hirano C, Hamaguchi H, Tsuchiya S, Tomura S (2000) Association of Trp64Arg polymorphism of the beta3-adrenergic receptor gene and no association of Gln223Arg polymorphism of the leptin receptor gene in Japanese schoolchildren with obesity. Int J Obes Relat Metab Disord 24:443–449. doi:10.1038/sj.ijo.0801177 PubMedCrossRef

Fietta P (2005) Focus on leptin, pleiotropic hormone. Minerva 96:65–75

Gröschl M, Topf H-G, Kratzsch J, Dötsch J, Rascher W, Rauh M (2005) Salivary leptin induces increased expression of growth factors in oral keratinocytes. J Mol Endocrinol 34:353–366. doi:10.1677/jme.1.01658 PubMedCrossRef

Gotoda T, Manning BS, Goldstone AP, Imrie H, Evans AL, Strosberg AD, McKeigue PM, Scott J, Aitman TJ (1997) Leptin receptor gene variation and obesity: lack of association in a white British male population. Hum Mol Genet 6:869–876. doi:10.1093/hmg/6.6.869 PubMedCrossRef

Hardwick JCH, Van Den Brink GR, Offerhaus GJ, Van Deventer SIH, Peppelenbosh MP (2001) Leptin is a growth factor for colonic epithelial cells. Gastroenterology 121:79–90. doi:10.1053/gast.2001.25490 PubMedCrossRef

Hoffstedt J, Eriksson P, Mottagui-Tabar S, Arner P (2002) A polymorphism in the leptin promoter region (−2548 G/A) influences gene expression and adipose tissue secretion of leptin. Horm Metab Res 34:355–359. doi:10.1055/s-2002-33466 PubMedCrossRef

Hu X, Juneja SC, Maihle NJ, Cleary MP (2002) Leptin a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst 94:1704–1711PubMed

Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, Takei Y, Sato N (2001) Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatol 34:288–297. doi:10.1053/jhep.2001.26518 CrossRef

International HapMap Consortium (2003) The International HapMapProject. Nature 426:789–796. doi:10.1038/nature02168 CrossRef

Konopleva M, Mikhail A, Estrov Z, Zhao S, Harris D, Sanchez-Williams G, Kornblau SM, Dong J, Kliche KO, Jiang S, Snodgrass HR, Estey EH, Andreeff M (1999) Expression and function of leptin receptor isoforms in myeloid leukaemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood 93:1668–1676PubMed

Konstantinides S, Schäfer K, Koschnick S, Loskutoff D (2001) Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 108:1533–1540PubMed

Kurahara S, Shinohara M, Ikebe T, Nakamura S, Beppu M, Hiraki A, Takeuchi H, Shirasuna K (1999) Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck 21:627–638. doi:10.1002/(SICI)1097-0347(199910)21:7<627::AID-HED7>3.0.CO;2-2

Laud K, Gourdou I, Pessemess L, Peyrat JP, Djiane J (2002) Identification of leptin receptors in human breast cancer: Functional activity in the T47-D breast cancer cell line. Mol Cell Endocrinol 188:219–226. doi:10.1016/S0303-7207(01)00678-5 PubMedCrossRef

Le Stunff C, Le Bihan C, Schrk NJ, Bougneres P (2000) A common promoter variant of the leptin gene is associated with changes in the relationship between serum leptin and fat mass in obese girls. Diabetes 49:2196–2200. doi:10.2337/diabetes.49.12.2196 PubMedCrossRef

Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, Klein AS, Bulkley GB, Bao C, Noble PW, Lane MD, Diehl AM (1998) Leptin regulates proinflammatory immune responses. FASEB J 12:57–65PubMed

Mammès O, Betoulle D, Aubert R, Giraud V, Tuzet S, Petiet A, Colas-Linhart N, Fumeron F (1998) Novel polymorphisms in the 5′ region of the LEP gene: association with leptin levels and response to low-calorie diet in human obesity. Diabetes 47:487–489. doi:10.2337/diabetes.47.3.487 PubMedCrossRef

Mammès O, Aubert R, Betoulle D, Péan F, Herbeth B, Visvikis S, Siest G, Fumeron F (2001) LEPR gene polymorphisms: associations with overweight, fat mass and response to diet in women. Eur J Clin Invest 31:398–404. doi:10.1046/j.1365-2362.2001.00843.x PubMedCrossRef

Morash B, Johnstone J, Leopold C, Li A, Murphy P, Ur E, Wilkinson M (2000) The regulation of leptin gene expressioin in the C6 glioblastoma cell line. Mol Cell Endocrinol 165:97–105. doi:10.1016/S0303-7207(00)00259-8 PubMedCrossRef

Neville BW, Day TA (2002) Oral cancer and precancerous lesions. CA Cancer J Clin 52:195–215PubMedCrossRef

Oliveira AM, Nashimento AG, LIoyd RV (2001) Leptin and leptin receptor mRNA are widely expressed in tumors of adipocytic differenciation. Mod Pathol 14:549–555. doi:10.1038/modpathol.3880349 PubMedCrossRef

Park HY, Kwon HM, Lim HJ, Hong BK, Lee JY, Park BE, Jang Y, Cho SY, Kim HS (2001) Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 33:95–99PubMed

Quehenberger P, Exner M, Sunder-Plassmann R, Ruzicka K, Bieglmayer C, Endler G, Muellner C, Speiser W, Wagner O (1998) Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res 83:1059–1066

Ribeiro R, Vasconcelos A, Costa S, Pinto D, Morais A, Oliveira J, Lobo F, Lopes C, Medeiros R (2004) Overexpressing leptin genetic polymorphism (−2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease. Prostate 59:268–274. doi:10.1002/pros.20004 PubMedCrossRef

Ribeiro R, Araújo AP, Coelho A, Catarino R, Pinto D, Araújo A, Calçada C, Lopes C, Medeiros R (2006) A functional polymorphism in the promoter region of leptin gene increases susceptibility for non-small cell lung cancer. Eur J Cancer 42:1188–1193. doi:10.1016/j.ejca.2006.02.004 PubMedCrossRef

Scully C, Bagan JV (2007) Recent advances in oral oncology. Oral Oncol 43:107–115. doi:10.1016/j.oraloncology.2006.12.007 PubMedCrossRef

Shigemura N, Miura H, Kusakabe Y, Hino A, Ninomiya Y (2003) Expression of leptin receptor (Ob-R) isoforms and signal transducers and activators of transcription (STATs) mRNAs in the mouse taste buds. Arch Histol Cytol 66:53–260. doi:10.1679/aohc.66.253 CrossRef

Sierra-Honigmann MR, Nath AK, Murakami C, García-Cardeña G, Papapetropoulos A, Sessa WC, Madge LA, Schechner JS, Schwabb MB, Polverini PJ, Flores-Riveros JR (1998) Biological action of leptin as an angiogenic factor. Science 281:1583–1585. doi:10.1126/science.281.5383.1683 CrossRef

Skibola CF, Holly EA, Forrest MS, Hubbard A, Bracci PM, Skibola DR, Hegedus C, Smith MT (2004) Body mass index, leptin and leptin receptor polymorphisms, and non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 13:779–786PubMed

Snoussi K, Strosberg AD, Bouaouina N, Ahmed SB, Helal AN, Chouchane L (2006) Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma. BMC Cancer 6:38. doi:10.1186/1471-2407-6-38 PubMedCrossRef

Thorisson G, Smith A, Krishnan L, Stein L (2005) The International HapMap Project web site. Genome Res 15:1592–1593. doi:10.1101/gr.4413105 PubMedCrossRef

Tsuchija T, Shimizu H, Horie T, Mori M (1999) Expression of leptin receptor in lung: leptin as a growth factor. Eur J Pharmacol 365:273–279. doi:10.1016/S0014-2999(98)00884-X CrossRef

Vairaktaris E, Yapijakis C, Kessler P, Vylliotis A, Ries J, Wiltfang J, Vassiliou S, Derka S, Neukam FW (2006a) Methylenetetrahydrofolate reductase polymorphism and minor increase of risk for oral cancer. J Cancer Res Clin Oncol 132:219–222. doi:10.1007/s00432-005-0065-5 PubMedCrossRef

Vairaktaris E, Yapijakis C, Serefoglou Z, Vylliotis A, Ries J, Nkenke E, Wiltfang J, Derka S, Vassiliou S, Springer I, Kessler P, Neukam FW (2006b) Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer. Oral Oncol 42:888–892. doi:10.1016/j.oraloncology.2005.12.005 PubMedCrossRef

Vairaktaris E, Yiannopoulos A, Vylliotis A, Yapijakis C, Derka S, Vassiliou S, Nkenke E, Serefoglou Z, Ragos V, Tsigris C, Vorris E, Critselis E, Avgoustidis D, Neukam FW, Patsouris E (2006c) Strong association of interleukin-6–174 G > C promoter polymorphism with increased risk for oral cancer. Int J Biol Markers 21(4):246–250PubMed

Vairaktaris E, Yapijakis C, Serefoglou Z, Derka S, Vassiliou S, Nkenke E, Vylliotis A, Wiltfang J, Avgoustidis D, Critselis E, Neukam FW, Patsouris E (2007a) The interleukin-8 (-251A/T) polymorphism is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol 33(4):504–507. doi:10.1016/j.ejso.2006.11.002 PubMedCrossRef

Vairaktaris E, Yapijakis C, Yiannopoulos A, Vassiliou S, Serefoglou Z, Vylliotis A, Nkenke E, Derka S, Critselis E, Avgoustidis D, Neukam FW, Patsouris E (2007b) Strong association of the tissue inhibitor of metalloproteinase-2 polymorphism with an increased risk of oral squamous cell carcinoma in Europeans. Oncol Rep 17(4):963–968PubMed

Vairaktaris E, Yannopoulos A, Vassiliou S, Serefoglou Z, Vylliotis A, Nkenke E, Critselis E, Avgoustidis D, Yapijakis C, Neukam FW, Patsouris E (2007c) Strong association of interleukin-4 (-590 C/T) polymorphism with increased risk for oral squamous cell carcinoma in Caucasians. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104(6):796–802. doi:10.1016/j.tripleo.2006.12.029 PubMedCrossRef

Vairaktaris E, Yapijakis C, Nkenke E, Vassiliou S, Vylliotis A, Nixon AM, Derka S, Ragos V, Spyridonidou S, Tsigris C, Neukam FW, Patsouris E (2007d) The 1040 C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor (TAFI) is associated with risk for oral cancer. Am J Hematol 82(11):1010–1012. doi:10.1002/ajh.20985 PubMedCrossRef

Vairaktaris E, Serefoglou Z, Yapijakis C, Vylliotis A, Nkenke E, Derka S, Vassiliou S, Avgoustidis D, Neukam FW, Patsouris E (2007e) High gene expression of matrix metalloproteinase-7 is associated with early stages of oral cancer. Anticancer Res 27(4B):2493–2498PubMed

Vairaktaris E, Yapijakis C, Serefoglou Z, Avgoustidis D, Critselis E, Spyridonidou S, Vylliotis A, Derka S, Vassiliou S, Nkenke E, Patsouris E (2008) Gene expression polymorphisms of interleukins-1β, -4, -6, -8, -10, and Tumor necrosis factors -α, -β: regression analysis of their effect upon oral squamous cell carcinoma. J Cancer Res Clin Oncol 134(8):821–832

van Rossum CT, Hoebee B, Seidell JC, Bouchard C, van Baak MA, de Groot CP, Chagnon M, de Graaf C, Saris WH (2002) Genetic factors as predictors of weight gain in young adult Dutch men and women. Int J Obes Relat Metab Disord 26:517–528. doi:10.1038/sj.ijo.0801964 PubMedCrossRef

Vineis P, Alavanja M, Buffler P, Fontham E, Franceschi S, Gao YT, Gupta PC, Hackshaw A, Matos E, Samet J, Sitas F, Smith J, Stayner L, Straif K, Thun MJ, Wichmann HE, Wu AH, Zaridze D, Peto R, Doll R (2004) Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 96:99–106PubMedCrossRef

Williams HK (2000) Molecular pathogenesis of oral carcinoma. J Clin Pathol 53:165–172. doi:10.1136/jcp.53.7.565 CrossRef

Yapijakis C, Vairaktaris E, Vassiliou S, Vylliotis A, Nkenke E, Nixon AM, Derka S, Spyridonidou S, Vorris E, Neukam FW, Patsouris E (2007) The low VEGF production allele of the +936 C/T polymorphism is strongly associated with increased risk for oral cancer. J Cancer Res Clin Oncol 133(10):787–791. doi:10.1007/s00432-007-0240-y PubMedCrossRef

Yiannakouris N, Yannakoulia M, Melistas L, Chan JL, Klimis-Zacas D, Mantrozos CS (2001) The Q223R polymorphism of the leptin receptor gene is significantly associated with obesity and predicts a small percentage of body weight and body composition variability. J Clin Endocrinol Metab 86:4434–4439. doi:10.1210/jc.86.9.4434 PubMedCrossRef

Yiannakouris N, Melistas L, Yannakoulia M, Mungal K, Mantzoros CS (2003) The 2548G/A polymorphism in the human leptin gene promoter region is associated with plasma free leptin levels; interaction with adiposity and gender in healthy subjects. Hormones 2:229–236PubMed

Yin N, Wang D, Zhang H, Yi X, Sun X, Shi B, Wu H, Wu G, Wang X, Shang Y (2004) Molecular Mechanisms Involved in the Growth Stimulation of Breast Cancer Cells by Leptin. Cancer Res 64:5870–5875. doi:10.1158/0008-5472.CAN-04-0655 PubMedCrossRef

Title: Association of leptin −2548G/A and leptin receptor Q223R polymorphisms with increased risk for oral cancer
Authors: Christos Yapijakis
Michael Kechagiadakis
Emeka Nkenke
Zoe Serefoglou
Dimitrios Avgoustidis
Antonis Vylliotis
Despina Perrea
Friedrich W. Neukam
Efstratios Patsouris
Eleftherios Vairaktaris
Publication date: 01-04-2009
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 4/2009
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-008-0494-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2009

Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment

DNA vaccination with a mutated p53 allele induces specific cytolytic T cells and protects against tumor cell growth and the formation of metastasis

Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate carcinoma

Socio-demographic characteristics of participation in the opportunistic German cervical cancer screening programme: results from the EPIC-Heidelberg cohort

Grade I chondrosarcoma of bone: the Münster experience

Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage